0001193125-26-120214.txt : 20260323 0001193125-26-120214.hdr.sgml : 20260323 20260323190754 ACCESSION NUMBER: 0001193125-26-120214 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260319 FILED AS OF DATE: 20260323 DATE AS OF CHANGE: 20260323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zakrzewski Joseph S CENTRAL INDEX KEY: 0001331852 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41331 FILM NUMBER: 26783797 MAIL ADDRESS: STREET 1: 509 WATERVIEW PLACE CITY: NEW HOPE STATE: PA ZIP: 18938 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AN2 Therapeutics, Inc. CENTRAL INDEX KEY: 0001880438 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 820606654 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1300 EL CAMINO REAL, SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: (650) 331-9090 MAIL ADDRESS: STREET 1: 1300 EL CAMINO REAL, SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0609 4 2026-03-19 0001880438 AN2 Therapeutics, Inc. ANTX 0001331852 Zakrzewski Joseph S false C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025 true false false false false Stock Option (right to buy) 3.91 2026-03-19 4 A false 99999 A 2031-04-29 Common Stock 99999 99999 D Stock Option (right to buy) 6.596 2026-03-19 4 D false 99999 D 2031-04-29 Common Stock 99999 0 D Stock Option (right to buy) 3.91 2026-03-19 4 A false 10362 A 2032-05-11 Common Stock 10362 10362 D Stock Option (right to buy) 17.28 2026-03-19 4 D false 10362 D 2032-05-11 Common Stock 10362 0 D Stock Option (right to buy) 3.91 2026-03-19 4 A false 23742 A 2033-06-06 Common Stock 23742 23742 D Stock Option (right to buy) 5.91 2026-03-19 4 D false 23742 D 2033-06-06 Common Stock 23742 0 D The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. The option is fully vested. On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. /s/ Lucy Day, Attorney-in-Fact for Joseph S. Zakrzewski 2026-03-23